This Week in Cardiology

Nov 21 2025 This Week in Cardiology

35 snips
Nov 21, 2025
This week, the discussion dives into groundbreaking findings from the CREST-2 trial, revealing new insights into treating carotid artery disease. The ongoing battle between prasugrel and ticagrelor continues, with recent evidence suggesting prasugrel holds an edge for high-risk diabetic patients. Plus, there's an intriguing look at coffee consumption's relationship with atrial fibrillation—could that morning cup actually lower your risk? Tune in for a blend of clinical updates and listener feedback that keeps healthcare professionals engaged!
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Complete Revascularization Results Are Nuanced

  • Patient-level meta-analyses can give a persuasive but potentially biased picture depending on included trials and sensitivity analyses.
  • John Mandrola argues the complete revascularization benefit may be driven by trials with non-STEMI or periprocedural MI counting issues, so results remain unconvincing to him.
ADVICE

Apply Clinical Judgment Over Trial Averages

  • Use clinical judgment and do not generalize trial averages to every patient, especially when trials exclude non-randomizable cases.
  • The onus is on clinicians to prove why doing more (like additional PCI) benefits a specific patient before proceeding.
INSIGHT

Drug Class Versus Individual Agent Effects Are Unclear

  • Class effects versus individual drug effects remain uncertain; trial context and patient selection may explain differing outcomes.
  • Mandrola cites bucindolol and BEST to illustrate how patient fragility and trial populations can drive apparent drug failures.
Get the Snipd Podcast app to discover more snips from this episode
Get the app